Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri

ÖRKEN NECİOĞLU, Dilek; Arsava, Ethem Murat; TOPCUOGLU, MEHMET; ÖZDEMİR, Atilla Özcan; Ozturk, Serefnur; GÜRKAS, Erdem

Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri

Mehmet Akif TOPÇUOĞLU, (Hacettepe Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Ankara, Türkiye)

Ethem Murat ARSAVA, (Hacettepe Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Ankara, Türkiye)

Atilla Özcan ÖZDEMİR, (Eskişehir Osmangazi Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Eskişehir, Türkiye)

Erdem GÜRKAS, (Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Nöroloji Kliniği, Ankara, Türkiye)

Dilek ÖRKEN NECİOĞLU, (İstanbul Bilim Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, İstanbul, Türkiye)

Şerefnur ÖZTÜRK (Selçuk Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Konya, Türkiye)

Türk Nöroloji Dergisi

4 1

Yıl: 2018 Cilt: 24 Sayı: 1 Sayfa Aralığı: 13 - 25 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri

Öz:

Akut iskemik inme tedavisinin ana elementlerinin başında gelen intravenöz (IV) doku plazminojen aktivatörü (tPA) kullanımının yeterince yaygınlaşamamasının en önemli nedenlerinden biri sık karşılaşılan birçok soruya yeterince yanıt veril(e)memiş olmasıdır. Bu derlemede akut inmede IV tPA tedavisi ile ilgili olarak meslektaşlarımızdan toplanan, daha çok uygulamada önemi olan sistemik soru ve sorunlar ile tedavinin komplikasyonlarına dair, sorulara güncel literatür temelinde yanıt verilmiş ve net tavsiyelerde bulunulmuştur

Anahtar Kelime:

Konular: Nörolojik Bilimler

Intravenous Thrombolytic Therapy in Acute Stroke: Frequent Systemic Problems and Solutions

Öz:

One of the most important reasons why the use of the intravenous (IV) tissue plasminogen activator (tPA), which is one of the key elements of acute ischemic stroke treatment, is not sufficiently widespread is the fact that many common questions have not been adequately answered. In this review, questions about systemic nonneurologic conditions, problems related with IV tPA treatment and complications of treatment, which were collected from our colleagues practicing in Turkey and which are more important in clinical practice, were answered on the basis of the current literature and clear recommendations are made

Anahtar Kelime:

Konular: Nörolojik Bilimler

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016;47:581-641.
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
3. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
4. TCSB. ACTILYSE 50 mg 1 flakon Kullanma Talimatı PDF Dosyası. Ulaşılan web sitesi: http://wwwilacrehbericom/pdfs/actilyse-50-mg-1-flakon-870d/ kt/ 2012; Ulaşım tarihi: 21/4/2017(Boehringer Ingelheim İlaç Tic. A.Ş. Güncelleme: 7 September 2012).
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
6. Bhatnagar P, Sinha D, Parker RA, Guyler P, O'Brien A. Intravenous thrombolysis in acute ischaemic stroke: a systematic review and metaanalysis to aid decision making in patients over 80 years of age. J Neurol Neurosurg Psychiatry 2011;82:712-717.
7. Asuzu D, Nystrom K, Amin H, Schindler J, Wira C, Greer D, Chi NF, Halliday J, Sheth KN. Comparison of 8 scores for predicting symptomatic intracerebral hemorrhage after IV thrombolysis. Neurocrit Care 2015;22:229-233.
8. Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR; VISTA Collaborators. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010;41:2840-2848.
9. IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST3]): a randomised controlled trial. Lancet 2012;379:2352-2363.
10. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-1935.
11. FDA. ACTIVASE (alteplase) for injection, for intravenous use. HIGHLIGHTS OF PRESCRIBING INFORMATION. Application 103172 This document contains: Label for ACTIVASE [Supplement 5203, Action Date 02/13/2015] 2015; https://www.accessdata.fda.gov/drugsatfda_docs/ label/2015/103172s5203lbl.pdf (accessed on april 20, 2017).
12. Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, Wahlgren N, Ahmed N; SITS Investigators. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012;43:1524-1531.
13. Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, Peterson ED, Hernandez AF, Fonarow GC, Schwamm LH, Smith EE. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 2012;43:2293-2299.
14. Tariq N, Adil MM, Saeed F, Chaudhry SA, Qureshi AI. Outcomes of thrombolytic treatment for acute ischemic stroke in dialysis-dependent patients in the United States. J Stroke Cerebrovasc Dis 2013;22:354-359.
15. Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, Marler JR, Tilley BC. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke 1998;29:1504-1509.
16. Desilles JP, Meseguer E, Labreuche J, Lapergue B, Sirimarco G, GonzalezValcarcel J, Lavallée P, Cabrejo L, Guidoux C, Klein I, Amarenco P, Mazighi M. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. Stroke 2013;44:1915-1923.
17. Ribo M, Molina C, Montaner J, Rubiera M, Delgado-Mederos R, Arenillas JF, Quintana M, Alvarez-Sabín J. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 2005;36:1705-1709.
18. Ribo M, Molina CA, Delgado P, Rubiera M, Delgado-Mederos R, Rovira A, Munuera J, Alvarez-Sabin J. Hyperglycemia during ischemia rapidly accelerates brain damage in stroke patients treated with tPA. J Cereb Blood Flow Metab 2007;27:1616-1622.
19. Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A, Mishra NK, Shuaib A, Wahlgren NG, Weimar C, Lees KR; VISTA Collaborators. Thrombolysis in stroke despite contraindications or warnings? Stroke 2013;44:727-733.
20. Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke 2008;39:2749-2755.
21. Newey CR, Cueva W, Vellipuram A, Hornik A. Medical Decision Making: Hyposphagma Prior to Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis 2016;25:181-182.
22. Gunnar RM, Passamani ER, Bourdillon PD, Pitt B, Dixon DW, Rapaport E, Fuster V, Reeves TJ, Karp RB, Russell RO Jr, et al. Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 1990;16:249-292.
23. Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, Vahanian A, Topol EJ, Califf RM. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:1606-1610.
24. Moudgil SS. Thrombolysis in acute ischemic stroke with vitreous hemorrhage. Arch Neurol 2009;66:1178.
25. Fugate JE, Rabinstein AA. Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke. Neurohospitalist 2015;5:110-121.
26. De Keyser J, Gdovinová Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 2007;38:2612-2618.
27. Guillan M, Alonso-Canovas A, Garcia-Caldentey J, Sanchez-Gonzalez V, Hernandez-Medrano I, Defelipe-Mimbrera A, Matute MC, Alonso-Arias MA, Alonso de Leciñana M, Masjuan J. Off-label intravenous thrombolysis in acute stroke. Eur J Neurol 2012;19:390-394.
28. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, Häppölä O, Lindsberg PJ, Mustanoja S, Piironen K, Pitkäniemi J, Rantanen K, Sairanen T, Salonen O, Silvennoinen H, Soinne L, Strbian D, Tiainen M, Kaste M. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010;41:1450-1458.
29. Network CS. Canadian Stroke Best Practices Management of Stroke Patients Who Receive Acute Thrombolytic Therapy (tPA) Order Set 2017. http:// www.strokebestpractices.ca/wp-content/uploads/2013/05/CSP-OS-02- Management-of-Stroke-Patients-who-Receive-tPA.pdf.
30. Casaubon LK, Boulanger JM, Blacquiere D, Boucher S, Brown K, Goddard T, Gordon J, Horton M, Lalonde J, LaRivière C, Lavoie P, Leslie P, McNeill J, Menon BK, Moses B, Penn M, Perry J, Snieder E, Tymianski D, Foley N, Smith EE, Gubitz G, Hill MD, Glasser E, Lindsay P; Heart and Stroke Foundation of Canada Canadian Stroke Best Practices Advisory Committee. Canadian Stroke Best Practice Recommendations: Hyperacute Stroke Care Guidelines, Update 2015. Int J Stroke 2015;10:924-940.
31. Cucchiara BL, Jackson B, Weiner M, Messe SR. Usefulness of checking platelet count before thrombolysis in acute ischemic stroke. Stroke 2007;38:1639- 1640.
32. Breuer L, Huttner HB, Kiphuth IC, Ringwald J, Hilz MJ, Schwab S, Köhrmann M. Waiting for platelet counts causes unsubstantiated delay of thrombolysis therapy. Eur Neurol 2013;69:317-320.
33. Mowla A, Kamal H, Lail NS, Vaughn C, Shirani P, Mehla S, RajabzadehOghaz H, Deline C, Ching M, Crumlish A, Sawyer RN. Intravenous Thrombolysis for Acute Ischemic Stroke in Patients with Thrombocytopenia. J Stroke Cerebrovasc Dis 2017;26:1414-1418.
34. Xian Y, Federspiel JJ, Grau-Sepulveda M, Hernandez AF, Schwamm LH, Bhatt DL, Smith EE, Reeves MJ, Thomas L, Webb L, Bettger JP, Laskowitz DT, Fonarow GC, Peterson ED. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. JAMA Neurol 2016;73:50-59.
35. [No authors listed]. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-2125.
36. Meseguer E, Labreuche J, Guidoux C, Lavallée PC, Cabrejo L, Sirimarco G, Valcarcel JG, Klein IF, Amarenco P, Mazighi M. Outcomes after stroke thrombolysis according to prior antiplatelet use. Int J Stroke 2015;10:163-169.
37. Pan X, Zhu Y, Zheng D, Liu Y, Yu F, Yang J. Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials. Int J Stroke 2015;10:317-323.
38. Luo S, Zhuang M, Zeng W, Tao J. Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta-analysis of 19 Studies. J Am Heart Assoc 2016;5:e003242.
39. Tsivgoulis G, Katsanos AH, Zand R, Sharma VK, Köhrmann M, Giannopoulos S, Dardiotis E, Alexandrov AW, Mitsias PD, Schellinger PD, Alexandrov AV. Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis. J Neurol 2017;264:1227-1235.
40. Zinkstok SM, Roos YB; ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 2012;380:731-737.
41. Actilyse Prescribing Information. wwwmedicinesorguk/ emc/medicine/308 2016.
42. Mazya MV, Lees KR, Markus R, Roine RO, Seet RC, Wahlgren N, Ahmed N; Safe Implementation of Thrombolysis in Stroke Investigators. Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013;74:266-274.
43. Ruecker M, Matosevic B, Willeit P, Kirchmayr M, Zangerle A, Knoflach M, Willeit J, Kiechl S. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology 2012;79:31-38.
44. Seet RC, Zhang Y, Moore SA, Wijdicks EF, Rabinstein AA. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2011;42:2333-2335.
45. Saposnik G, Fang J, Kapral MK, Tu JV, Mamdani M, Austin P, Johnston SC; Investigators of the Registry of the Canadian Stroke Network (RCSN); Stroke Outcomes Research Canada (SORCan) Working Group. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke 2012;43:1315-1322.
46. Dangayach NS, Panchabhai TS. Point-of-care international normalized ratio measurements to assess eligibility for thrombolysis in acute ischemic stroke: some thoughts. Stroke 2010;41:e431.
47. Rizos T, Herweh C, Jenetzky E, Lichy C, Ringleb PA, Hacke W, Veltkamp R. Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke 2009;40:3547-3551.
48. Barreto AD, Ford GA, Shen L, Pedroza C, Tyson J, Cai C, Rahbar MH, Grotta JC; ARTSS-2 Investigators. Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke 2017;48:1608-1616.
49. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015;373:511-520.
50. Diener HC, Bernstein R, Butcher K, Campbell B, Cloud G, Davalos A, Davis S, Ferro JM, Grond M, Krieger D, Ntaios G, Slowik A, Touzé E. Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion. Int J Stroke 2017;12:9-12.
51. Matute MC, Guillán M, García-Caldentey J, Buisan J, Aparicio M, Masjuan J, Alonso de Leciñana M. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011;106:178- 179.
52. Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cangür H, Daffertshofer M, Edelbusch S, Gröschel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, Müllges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, Röther J, Rossi R, Schäfer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection. Int J Stroke 2017;12:383-391.
53. Xian Y, Federspiel JJ, Hernandez AF, Laskowitz DT, Schwamm LH, Bhatt DL, Smith EE, Fonarow GC, Peterson ED. Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation 2017;135:1024-1035.
54. Tsivgoulis G, Safouris A. Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated With Non-Vitamin K Antagonist Oral Anticoagulants: An Editorial Review. Stroke 2017;48:2031-2033.
55. Seiffge DJ, Hooff RJ, Nolte CH, Béjot Y, Turc G, Ikenberg B, Berge E, Persike M, Dequatre-Ponchelle N, Strbian D, Pfeilschifter W, Zini A, Tveiten A, Næss H, Michel P, Sztajzel R, Luft A, Gensicke H, Traenka C, Hert L, Scheitz JF, De Marchis GM, Bonati LH, Peters N, Charidimou A, Werring DJ, Palm F, Reinhard M, Niesen WD, Nagao T, Pezzini A, Caso V, Nederkoorn PJ, Kägi G, von Hessling A, Padjen V, Cordonnier C, Erdur H, Lyrer PA, Brouns R, Steiner T, Tatlisumak T, Engelter ST; NOACISP Study Group. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation 2015;132:1261-1269.
56. Shahjouei S, Tsivgoulis G, Bavarsad Shahripour R, Jones GM, Alexandrov AV, Zand R. Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants--Case Series and Systematic Review of Reported Cases. J Stroke Cerebrovasc Dis 2015;24:2685-2693.
57. Matute MC, Masjuan J, Egido JA, Fuentes B, Simal P, Díaz-Otero F, Reig G, Díez-Tejedor E, Gil-Nuñez A, Vivancos J, Alonso de Leciñana M. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc Dis 2012;33:231-239.
58. Xian Y, Hernandez AF, Harding T, Fonarow GC, Bhatt DL, Suter RE, Khan Y, Schwamm LH, Peterson ED. Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. Am Heart J 2016;182:28-35.
59. Ovbiagele B, Smith EE, Schwamm LH, Grau-Sepulveda MV, Saver JL, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke. Circ Cardiovasc Qual Outcomes 2014;7:929-935.
60. Hsieh CY, Lin HJ, Sung SF, Yang YH, Lai EC, Hsieh HC, Chen CH. Does renal dysfunction modify the effect of intravenous thrombolysis for acute ischemic stroke within 4.5 hours of onset? A multicenter observational study. J Stroke Cerebrovasc Dis 2015;24:673-679.
61. Wein TH, Hickenbottom SL, Morgenstern LB, Demchuk AM, Grotta JC. Safety of tissue plasminogen activator for acute stroke in menstruating women. Stroke 2002;33:2506-2508.
62. Biswas S, Ajani AE. Interventionalists beware: the apical thrombus! Cardiovasc Revasc Med 2012;13:143.
63. Kasner SE, Villar-Cordova CE, Tong D, Grotta JC. Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke. Neurology 1998;50:1857-1859.
64. Stafford PJ, Strachan CJ, Vincent R, Chamberlain DA. Multiple microemboli after disintegration of clot during thrombolysis for acute myocardial infarction. BMJ 1989;299:1310-1312.
65. Derex L, Nighoghossian N, Perinetti M, Honnorat J, Trouillas P. Thrombolytic therapy in acute ischemic stroke patients with cardiac thrombus. Neurology 2001;57:2122-2125.
66. Yang CJ, Chen PC, Lin CS, Tsai CL, Tsai SH. Thrombolytic therapyassociated acute myocardial infarction in patients with acute ischemic stroke: A treatment dilemma. Am J Emerg Med 2017;35:804.
67. Kobayashi M, Tanaka R, Yamashiro K, Ueno Y, Kato E, Miura S, Daida H, Hattori N. Pre-existing Mobile Cardiac Thrombus and the Risk of Early Recurrent Embolism after Intravenous Thrombolysis: A Case Report. J Stroke Cerebrovasc Dis 2015;24:161-163.
68. Acampa M, Guideri F, Tassi R, D'Andrea P, Marotta G, Lo Giudice G, Martini G. Thrombolytic treatment of cardiac myxoma-induced ischemic stroke: a review. Curr Drug Saf 2014;9:83-88.
69. Mendes A, Mendonca T, Sousa A, Moreira G, Carvalho M. Stroke secondary to aortic dissection treated with a thrombolytic: a successful case. Neurol Sci 2012;33:107-110.
70. Noel M, Short J, Farooq MU. Thrombolytic therapy in a patient with acute ischemic stroke caused by aortic dissection. Clin Neurol Neurosurg 2010;112:695-696.
71. Graber JJ, Nayak L, Deangelis LM. Use of recombinant tissue plasminogen activator in cancer patients with acute stroke. J Neurooncol 2012;107:571- 573.
72. Murthy SB, Karanth S, Shah S, Shastri A, Rao CP, Bershad EM, Suarez JI. Thrombolysis for acute ischemic stroke in patients with cancer: a population study. Stroke 2013;44:3573-3576.
73. Masrur S, Abdullah AR, Smith EE, Hidalgo R, El-Ghandour A, Rordorf G, Schwamm LH. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy. J Stroke Cerebrovasc Dis 2011;20:124- 130.
74. Cappellari M, Carletti M, Micheletti N, Tomelleri G, Ajena D, Moretto G, Bovi P. Intravenous alteplase for acute ischemic stroke in patients with current malignant neoplasm. J Neurol Sci 2013;325:100-102.
75. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, Christianson TJ. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004;35:2418-2424.
76. Foell RB, Silver B, Merino JG, Wong EH, Demaerschalk BM, Poncha F, Tamayo A, Hachinski V. Effects of thrombolysis for acute stroke in patients with pre-existing disability. CMAJ 2003;169:193-197.
77. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke 2007;38:3205-3212.
78. Karlinski M, Kobayashi A, Czlonkowska A, Mikulik R, Vaclavik D, Brozman M, Svigelj V, Csiba L, Fekete K, Kõrv J, Demarin V, Vilionskis A, Jatuzis D, Krespi Y, Ahmed N, Wahlgren N; Safe Implementation of Treatments in Stroke-Eastern Europe (SITS-EAST) Investigators. Role of preexisting disability in patients treated with intravenous thrombolysis for ischemic stroke. Stroke 2014;45:770-775.
79. Hong KS, Saver JL. Years of disability-adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke. Stroke 2010;41:471-477.
80. Eriksson M, Jonsson F, Appelros P, Asberg KH, Norrving B, Stegmayr B, Terént A, Asplund K; Riks-Stroke Collaboration. Dissemination of thrombolysis for acute ischemic stroke across a nation: experiences from the Swedish stroke register, 2003 to 2008. Stroke 2010;41:1115-1122.
81. Hughes S. DAWN: Thrombectomy Effective Up to 24 Hours After Stroke. 2017. http://www.medscape.com/viewarticle/880144#vp_1
82. Zinkstok SM, Engelter ST, Gensicke H, Lyrer PA, Ringleb PA, Artto V, Putaala J, Haapaniemi E, Tatlisumak T, Chen Y, Leys D, Sarikaya H, Michel P, Odier C, Berrouschot J, Arnold M, Heldner MR, Zini A, Fioravanti V, Padjen V, Beslac-Bumbasirevic L, Pezzini A, Roos YB, Nederkoorn PJ. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke 2013;44:1080-1084.
83. Hemmen TM, Meyer BC, McClean TL, Lyden PD. Identification of nonischemic stroke mimics among 411 code strokes at the University of California, San Diego, Stroke Center. J Stroke Cerebrovasc Dis 2008;17:23- 25.
84. Scott PA, Silbergleit R. Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes. Ann Emerg Med 2003;42:611-618.
85. Evans MRB, White P, Cowley P, Werring DJ. Revolution in acute ischaemic stroke care: a practical guide to mechanical thrombectomy. Pract Neurol 2017;17:252-265.
86. Peker A, Arsava EM, Topcuglu MA, Arat A. Akut İskemik İnme: Mekanik Trombektomi Cihazı Olarak "Stentriever" Kullanımı. Turkiye Klinikleri J Radiol-Special Topics 2017;10:86-92.
87. Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, Watson T, Goyal M, Demchuk AM. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 2010;41:2254-2258.
88. Rudd T, Bowen A, James M, Young G. National clinical guideline for stroke Prepared by the Intercollegia the Stroke Working Party. 2016. https://www. strokeaudit.org/Guideline/Full-Guideline.aspx.
89. Demeestere J, Garcia-Esperon C, Lin L, Bivard A, Ang T, Smoll NR, Garnett A, Loudfoot A, Miteff F, Spratt N, Parsons M, Levi C. Validation of the National Institutes of Health Stroke Scale-8 to Detect Large Vessel Occlusion in Ischemic Stroke. J Stroke Cerebrovasc Dis 2017;26:1419-1426.
90. Pérez de la Ossa N, Carrera D, Gorchs M, Querol M, Millán M, Gomis M, Dorado L, López-Cancio E, Hernández-Pérez M, Chicharro V, Escalada X, Jiménez X, Dávalos A. Design and validation of a prehospital stroke scale to predict large arterial occlusion: the rapid arterial occlusion evaluation scale. Stroke 2014;45:87-91.
91. Carrera D, Campbell BC, Cortés J, Gorchs M, Querol M, Jiménez X, Millán M, Dávalos A, Pérez de la Ossa N. Predictive Value of Modifications of the Prehospital Rapid Arterial Occlusion Evaluation Scale for Large Vessel Occlusion in Patients with Acute Stroke. J Stroke Cerebrovasc Dis 2017;26:74-77.
92. Heldner MR, Hsieh K, Broeg-Morvay A, Mordasini P, Bühlmann M, Jung S, Arnold M, Mattle HP, Gralla J, Fischer U. Clinical prediction of large vessel occlusion in anterior circulation stroke: mission impossible? J Neurol 2016;263:1633-1640.
93. Turc G, Maïer B, Naggara O, Seners P, Isabel C, Tisserand M, Raynouard I, Edjlali M, Calvet D, Baron JC, Mas JL, Oppenheim C. Clinical Scales Do Not Reliably Identify Acute Ischemic Stroke Patients With Large-Artery Occlusion. Stroke 2016;47:1466-1472.
94. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Dávalos A, Majoie CB, van der Lugt A, de Miquel MA, Donnan GA, Roos YB, Bonafe A, Jahan R, Diener HC, van den Berg LA, Levy EI, Berkhemer OA, Pereira VM, Rempel J, Millán M, Davis SM, Roy D, Thornton J, Román LS, Ribó M, Beumer D, Stouch B, Brown S, Campbell BC, van Oostenbrugge RJ, Saver JL, Hill MD, Jovin TG; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016;387:1723- 1731.
95. Topcuoglu MA, Arsava EM. Stroke Treatment: Current News and Developments Turk J Neurol 2016;22:145-147.
96. Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH, Broderick JP, Chen X, Chen G, Sharma VK, Kim JS, Thang NH, Cao Y, Parsons MW, Levi C, Huang Y, Olavarría VV, Demchuk AM, Bath PM, Donnan GA, Martins S, Pontes-Neto OM, Silva F, Ricci S, Roffe C, Pandian J, Billot L, Woodward M, Li Q, Wang X, Wang J, Chalmers J; ENCHANTED Investigators and Coordinators. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. N Engl J Med 2016;374:2313-2323.

APA	TOPCUOGLU M, Arsava E, ÖZDEMİR A, GÜRKAS E, ÖRKEN NECİOĞLU D, Ozturk S (2018). Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. , 13 - 25.
Chicago	TOPCUOGLU MEHMET,Arsava Ethem Murat,ÖZDEMİR Atilla Özcan,GÜRKAS Erdem,ÖRKEN NECİOĞLU Dilek,Ozturk Serefnur Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. (2018): 13 - 25.
MLA	TOPCUOGLU MEHMET,Arsava Ethem Murat,ÖZDEMİR Atilla Özcan,GÜRKAS Erdem,ÖRKEN NECİOĞLU Dilek,Ozturk Serefnur Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. , 2018, ss.13 - 25.
AMA	TOPCUOGLU M,Arsava E,ÖZDEMİR A,GÜRKAS E,ÖRKEN NECİOĞLU D,Ozturk S Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. . 2018; 13 - 25.
Vancouver	TOPCUOGLU M,Arsava E,ÖZDEMİR A,GÜRKAS E,ÖRKEN NECİOĞLU D,Ozturk S Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. . 2018; 13 - 25.
IEEE	TOPCUOGLU M,Arsava E,ÖZDEMİR A,GÜRKAS E,ÖRKEN NECİOĞLU D,Ozturk S "Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri." , ss.13 - 25, 2018.
ISNAD	TOPCUOGLU, MEHMET vd. "Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri". (2018), 13-25.

APA	TOPCUOGLU M, Arsava E, ÖZDEMİR A, GÜRKAS E, ÖRKEN NECİOĞLU D, Ozturk S (2018). Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. Türk Nöroloji Dergisi, 24(1), 13 - 25.
Chicago	TOPCUOGLU MEHMET,Arsava Ethem Murat,ÖZDEMİR Atilla Özcan,GÜRKAS Erdem,ÖRKEN NECİOĞLU Dilek,Ozturk Serefnur Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. Türk Nöroloji Dergisi 24, no.1 (2018): 13 - 25.
MLA	TOPCUOGLU MEHMET,Arsava Ethem Murat,ÖZDEMİR Atilla Özcan,GÜRKAS Erdem,ÖRKEN NECİOĞLU Dilek,Ozturk Serefnur Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. Türk Nöroloji Dergisi, vol.24, no.1, 2018, ss.13 - 25.
AMA	TOPCUOGLU M,Arsava E,ÖZDEMİR A,GÜRKAS E,ÖRKEN NECİOĞLU D,Ozturk S Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. Türk Nöroloji Dergisi. 2018; 24(1): 13 - 25.
Vancouver	TOPCUOGLU M,Arsava E,ÖZDEMİR A,GÜRKAS E,ÖRKEN NECİOĞLU D,Ozturk S Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri. Türk Nöroloji Dergisi. 2018; 24(1): 13 - 25.
IEEE	TOPCUOGLU M,Arsava E,ÖZDEMİR A,GÜRKAS E,ÖRKEN NECİOĞLU D,Ozturk S "Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri." Türk Nöroloji Dergisi, 24, ss.13 - 25, 2018.
ISNAD	TOPCUOGLU, MEHMET vd. "Akut İnme Tedavisinde İntravenöz Trombolitik Tedavi: Sık Görülen Sistemik Sorunlar ve Çözümleri". Türk Nöroloji Dergisi 24/1 (2018), 13-25.